Ovarian cancer vaccine - Life Research Technologies

Drug Profile

Ovarian cancer vaccine - Life Research Technologies

Alternative Names: Autologous TERT-mRNA survivin peptide-loaded dendritic cell vaccine - CELLMED; Procure; TERT-mRNA and survivin-peptide double loaded dendritic cells

Latest Information Update: 11 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator LIFE RESEARCH Technologies
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action CD4-positive T lymphocyte stimulants; CD8 positive T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Ovarian cancer

Most Recent Events

  • 11 Mar 2017 Discontinued - Phase-I/II for Ovarian cancer (Late-stage disease, Adjuvant therapy) in Austria and Hungary (Intradermal)
  • 11 Apr 2016 Life Research Technologies plans a phase IIb trial for Ovarian cancer (Recurrent, Late-stage disease) in Germany (CELLMED website)
  • 30 Sep 2010 Phase-I/II clinical trials in Ovarian cancer in Austria (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top